We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+13.31%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$118M
AUM Growth
+$4.41M
Cap. Flow
-$8.19M
Cap. Flow %
-6.92%
Top 10 Hldgs %
44.84%
Holding
84
New
17
Increased
12
Reduced
22
Closed
11

Top Buys

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$6.63M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$3.31M
3
CLLS
Cellectis
CLLS
+$1.61M
4
RIGL icon
Rigel Pharmaceuticals
RIGL
+$1.21M
5
BLRX
BioLineRX
BLRX
+$1.07M

Top Sells

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$2.56M
2
AERI
Aerie Pharmaceuticals
AERI
+$2.3M
3
DERM
Dermira, Inc.
DERM
+$2.28M
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$2.21M
5
TSRO
TESARO, Inc.
TSRO
+$2.08M

Sector Composition

Rank Sector Weight
1 Healthcare 93.12%
2 Miscellaneous 6.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LOXO
1
DELISTED
Loxo Oncology, Inc
LOXO
$12.7M 10.7%
300,722
+161,000
+115% +$6.63M
ATRC icon
2
AtriCure
ATRC
$2.47B
$9.71M 8.21%
506,946
-12,000
-2% -$210K
NXTM
3
DELISTED
NxStage Medical Inc.
NXTM
$5.8M 4.9%
216,119
-20,000
-8% -$552K
ALDR
4
DELISTED
Alder Biopharmaceuticals
ALDR
$4.6M 3.89%
221,013
– –
BCRX icon
5
BioCryst Pharmaceuticals
BCRX
$2.51B
$4.54M 3.84%
541,128
+475,228
+721% +$3.31M
VIRX
6
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$3.56M 3.01%
24,787
-7,601
-23% -$1.09M
BPMC
7
DELISTED
Blueprint Medicines
BPMC
$3.3M 2.79%
82,500
+10,000
+14% +$358K
LKFT
8
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$3.05M 2.58%
35,359
-30,709
-46% -$2.21M
ONC
9
BeOne Medicines Ltd
ONC
$41.5B
$2.97M 2.52%
81,231
-38,610
-32% -$1.41M
AGTC
10
DELISTED
Applied Genetic Technologies Corporation
AGTC
$2.84M 2.4%
411,000
+124,702
+44% +$974K
ARDX icon
11
Ardelyx
ARDX
$984M
$2.81M 2.37%
221,738
+47,743
+27% +$628K
PODD icon
12
Insulet
PODD
$10.1B
$2.74M 2.31%
63,484
-10,000
-14% -$429K
SYRE icon
13
Spyre Therapeutics
SYRE
$7.97B
$2.61M 2.21%
14,016
– –
IBB icon
14
iShares Biotechnology ETF
IBB
$10.5B
$2.55M 2.16%
26,100
– –
NBIX icon
15
Neurocrine Biosciences
NBIX
$15.7B
$2.53M 2.14%
58,508
-7,500
-11% -$321K
MGNX icon
16
MacroGenics
MGNX
$263M
$2.22M 1.88%
119,200
+30,000
+34% +$579K
BEAT
17
DELISTED
BioTelemetry, Inc.
BEAT
$2.17M 1.84%
75,000
– –
AERI
18
DELISTED
Aerie Pharmaceuticals
AERI
$2.12M 1.79%
46,770
-51,600
-52% -$2.3M
SPNC
19
DELISTED
Spectranetics Corp
SPNC
$1.91M 1.61%
65,496
– –
RDUS
20
DELISTED
Radius Health, Inc.
RDUS
$1.89M 1.6%
48,809
-5,045
-9% -$212K
CLLS
21
Cellectis
CLLS
$342M
$1.83M 1.55%
+76,404
New +$1.61M
TVRD
22
Tvardi Therapeutics
TVRD
$24.3M
$1.75M 1.48%
2,648
-3,172
-55% -$1.69M
IMMU
23
DELISTED
Immunomedics Inc
IMMU
$1.63M 1.38%
252,574
-307,100
-55% -$1.56M
CDTX
24
DELISTED
Cidara Therapeutics
CDTX
$1.63M 1.38%
10,423
+2,427
+30% +$426K
FOMX
25
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$1.61M 1.36%
325,667
+57,600
+21% +$554K
1
2 3 4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q1 2017 Portfolio in Review

As of Q1 2017, DAFNA Capital Management held 84 positions worth $118M, up 3.9% from $114M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

DAFNA Capital Management withdrew a net $8.19M in Q1 2017, closing 11 positions and reducing 22 holdings. Its most notable exit was Cytokinetics, an estimated $2.56M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier, followed by Miscellaneous.

Against the trend, DAFNA Capital Management opened a new position in Cellectis worth $1.83M.

  • DAFNA Capital Management's largest Q1 2017 buy was Cellectis: 76,404 shares worth $1.83M.
  • DAFNA Capital Management added most to Loxo Oncology, Inc in Q1 2017, an estimated $6.63M increase.
  • DAFNA Capital Management's biggest Q1 2017 reduction was Aerie Pharmaceuticals, cutting an estimated $2.3M.
  • DAFNA Capital Management fully exited Cytokinetics in Q1 2017, selling an estimated $2.56M.
  • DAFNA Capital Management's ten largest holdings make up 45% of its $118M portfolio in Q1 2017.
  • DAFNA Capital Management opened 17 new positions and closed 11 in Q1 2017.
  • DAFNA Capital Management's portfolio value rose 3.9% quarter-over-quarter to $118M.

Based on DAFNA Capital Management's 13F filing for Q1 2017, filed 15 May 2017.